Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Consultations on compound monograph documents

51 consultations on documents of this type.

Consultations

51 documents · page 1 of 3
  • CEI-CP-076OpenCompound monograph04 Jul 2026 – 15 Aug 2026

    Consultation on the draft monograph for SS-31 (elamipretide), which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the…

    16 submissions4 not accepted
  • CEI-CP-044OpenCompound monograph21 Jul 2026 – 01 Sep 2026

    Consultation on the draft monograph for CJC-1295, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    13 submissions
  • CEI-CP-039OpenCompound monograph05 Aug 2026 – 02 Sep 2026

    Consultation on the draft monograph for amycretin, a co-agonist at the glucagon-like peptide-1 and amylin receptors. The draft grades the principal assessed outcome at low certainty on the basis of early-phase evidence, and records that no…

    16 submissions1 not accepted
  • CEI-CP-049OpenCompound monograph07 Aug 2026 – 18 Sep 2026

    Consultation on the draft monograph for Exenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at high certainty and states the basis for that…

    8 submissions2 not accepted
  • CEI-CP-030ClosedCompound monograph13 Apr 2026 – 12 Jun 2026

    Consultation on the draft monograph for orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist. The draft assesses a compound whose phase 3 programme was reporting during the consultation window, and grades the…

    10 submissions2 not accepted
  • CEI-CP-075ClosedCompound monograph12 Apr 2026 – 11 Jun 2026

    Consultation on the draft monograph for Sermorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    9 submissions
  • CEI-CP-059ClosedCompound monograph10 May 2026 – 07 Jun 2026

    Consultation on the draft monograph for KPV, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…

    15 submissions1 not accepted
  • CEI-CP-072ClosedCompound monograph12 Apr 2026 – 07 Jun 2026

    Consultation on the draft monograph for PT-141 (bremelanotide), which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the…

    17 submissions1 not accepted
  • CEI-CP-071ClosedCompound monograph07 May 2026 – 06 Jun 2026

    Consultation on the draft monograph for Pramlintide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    15 submissions2 not accepted
  • CEI-CP-067ClosedCompound monograph08 May 2026 – 05 Jun 2026

    Consultation on the draft monograph for MOTS-c, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…

    8 submissions1 not accepted
  • CEI-CP-062ClosedCompound monograph01 May 2026 – 29 May 2026

    Consultation on the draft monograph for Lixisenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    10 submissions1 not accepted
  • CEI-CP-040ClosedCompound monograph20 Jan 2026 – 21 Mar 2026

    Consultation on the draft monograph for 5-amino-1MQ, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    6 submissions1 not accepted
  • CEI-CP-083ClosedCompound monograph15 Jan 2026 – 12 Mar 2026

    Consultation on the draft monograph for Thymosin beta-4, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for…

    15 submissions1 not accepted
  • CEI-CP-034ClosedCompound monograph27 Jan 2026 – 10 Mar 2026

    Consultation on the draft monograph for retatrutide, a triple agonist at the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors. The principal assessed outcome is graded at low certainty because…

    14 submissions3 not accepted
  • CEI-CP-047ClosedCompound monograph18 Jan 2026 – 01 Mar 2026

    Consultation on the draft monograph for Ecnoglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    7 submissions1 not accepted
  • CEI-CP-066ClosedCompound monograph17 Jan 2026 – 14 Feb 2026

    Consultation on the draft monograph for Melanotan-II, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    4 submissions1 not accepted
  • CEI-CP-048ClosedCompound monograph06 Jan 2026 – 03 Feb 2026

    Consultation on the draft monograph for Epithalon, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    5 submissions1 not accepted
  • CEI-CP-065ClosedCompound monograph08 Nov 2025 – 20 Dec 2025

    Consultation on the draft monograph for Mazdutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    9 submissions1 not accepted
  • CEI-CP-057ClosedCompound monograph16 Oct 2025 – 15 Nov 2025

    Consultation on the draft monograph for Ipamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    10 submissions1 not accepted
  • CEI-CP-043ClosedCompound monograph31 Jul 2025 – 29 Sep 2025

    Consultation on the draft monograph for CagriSema (cagrilintide with semaglutide), which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate…

    5 submissions1 not accepted

page 1 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.